Structural basis for inhibition of human PNP by immucillin-H

Biochemical and Biophysical Research Communications

Volumn 309, Issue 4, 2003, Pages 917-922

  De Azevedo Jr , Walter Filgueira ^a,b   Canduri, Fernanda ^a,b   Dos Santos, Denis Marangoni ^a,b   Pereira, José Henrique ^a,b   Dias, Márcio Vinicius Bertacine ^a   Silva, Rafael Guimarães ^c   Mendes, Maria Anita ^a,b   Basso, Luiz Augusto ^c   Palma, Mário Sérgio ^a,b   Santos, Diógenes Santiago ^c,d  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Drug design; Immucillin H; PNP; Structure; Synchrotron radiation

Indexed keywords

1 (9 DEAZAHYPOXANTHIN 9 YL) 1,4 DIDEOXY 1,4 IMINO DEXTRO RIBITOL; ANTIMITOTIC AGENT; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG EFFECT; DRUG PROTEIN BINDING; ENZYME DEGRADATION; ENZYME INHIBITION; LYMPHOCYTE PROLIFERATION; MITOSIS INHIBITION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SYNCHROTRON RADIATION; T LYMPHOCYTE;

EID: 0141788217     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.08.094     Document Type: Article

References (41)

1. Stoop W., Zegers B.J.M., Hendrickx G.F.M., van Heukelom L.H.S., Staal G.E.J., de Bree P.K., Wadman S.K., Ballieux R.E. Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency. N. Engl. J. Med. 296:1977;651-655.
2. Levinson W., Jawetz E. Medical Microbiology and Immunology. 2000;Lange Medical Books/McGraw-Hill, New York. pp. 344-363.
3. Banthia S., Montgomery J.A., Johnson H.G., Walsh G.M. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP. Immunopharmacology. 35:1996;53-63.
4. Mitchell B.S., Meijias E., Daddona P.E., Kelley W.N. Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T-cells. Proc. Natl. Acad. Sci. USA. 75:1978;5011-5014.
5. Stoeckler J.D. Glazer R.I. Developments in Cancer Chemotherapy. 1984;35-60 CRC Press, Bocca Raton, FL.
6. Kicska G., Long L., Hörig H., Fairchild G., Tyler P.C., Furneaux R.H., Schramm V.L., Kaufman H.L. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc. Natl. Acad. Sci. USA. 98:2001;4593-4598.
7. Bennett L.L. Jr., Allan P.W., Noker P.E., Rose L.M., Niwas S., Montgomery J.A., Erion M.D. Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds. J. Pharmacol. Exp. Ther. 266:1993;707-714.
8. Parks R.E. Jr., Agarwal R.P. Boyer P.D. The Enzymes. 1972;483-514 Academic Press, New York.
9. Schramm V.L. Enzymatic transition states and transition state analog design. Annu. Rev. Biochem. 67:1998;693-720.
10. Stoeckler J.D., Cambor C., Parks R.E. Jr. Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleosides substrates. Biochemistry. 19:1980;102-107.
11. Porter D.J.T. Purine nucleoside phosphorylase. Kinetic mechanism of the enzyme from calf spleen. J. Biol. Chem. 267:1992;7342-7351.
12. Silva R.G., Carvalho L.P., Oliveira J.S., Pinto C.A., Mendes M.A., Palma M.S., Basso L.A., Santos D.S. Cloning, overexpression, and purification of functional human purine nucleoside phosphorylase. Protein Expr. Purif. 27(1):2003;158-164.
13. Cook W.J., Ealick S.E., Bugg C.E., Stoeckler J.D., Parks R.E. Jr. J. Biol. Chem. 256:1981;4079-4080.
14. Ealick S.E., Babu Y.S., Bugg C.E., Erion M.D., Guida W.C., Montgomery J.A., Secrist III J.A. Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors. Proc. Natl. Acad. Sci. USA. 91:1991;11540-11544.
15. Collaborative Computational Project, No. 4. Acta Crystallogr. D 50 (1994) 760-763.
16. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A. 50:1994;157-163.
17. De Azevedo W.F. Jr., Canduri F., Santos D.M., Silva R.G., Oliveira J.S., Carvalho L.P.S., Basso L.A., Mendes M.A., Palma M.S., Santos D.S. Crystal structure of human purine nucleoside phosphorylase at 2.3. Å resolution Biochem. Biophys. Res. Commun. 308:2003;545-552.
18. Santos D.M., Canduri F., Pereira J.H., Dias M.V.B., Silva R.G., Mendes M.A., Palma M.S., Basso L.A., de Azevedo W.F., Santos D.S. Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir. Biochem. Biophys. Res. Commun. 308:2003;553-559.
19. Brünger A.T. X-PLOR Version 3.1: A System for Crystallography and NMR. 1992;Yale University Press, New Haven.
20. R.A. Laskowski, M.W. MacArthur, D.K. Smith, D.T. Jones, E.G. Hutchinson, A.L. Morris, D. Naylor, D.S. Moss, J.M. Thorton, PROCHECK v.3.0 - Program to Check the Stereochemistry Quality of Protein Structures - Operating Instructions, 1994.
21. McRee D.E. XtalView/Xfit - a versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125:1999;156-165.
22. Luzzati P.V. Traitement statistique des erreurs dans la determination des structures cristallines. Acta Crystallogr. 5:1952;802-810.
23. Erion M.D., Takabayashi K., Smith H.B., Kessi J., Wagner S., Hönger S., Shames S.L., Ealick S.E. Purine nucleoside phosphorylase. 1. Structure-function studies. Biochemistry. 36:1997;11725-11734.
24. Ealick S.E., Rule S.A., Carter D.C., Greenhough T.J., Babu Y.S., Cook W.J., Habash J., Helliwell J.R., Stoeckler J.D., Parks R.E. Jr., Chen S.-F., Bugg C.E. Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2. Å resolution J. Biol. Chem. 265(3):1990;1812-1820.
25. Fedorov A., Shi W., Kicska G.A., Fedorov E.V., Tyler P.C., Furneaux R.H., Hanson J.C., Gainsford G.J., Larese J.Z., Schramm V.L., Almo S.C. Transition state structure of purine nucleoside phosphorylase and principles of atomic motion in enzymatic catalysis. Biochemistry. 40:2001;853-860.
26. Mao C., Cook W.J., Zhou M., Federov A.A., Almo S.C., Ealick S.E. Calf spleen purine nucleoside phosphorylase complexed with substrates and substrates analogues. Biochemistry. 37:1998;7135-7146.
27. Canduri F., Teodoro L.G.V.L., Lorenzi C.C.B., Hial V., Gomes R.A.S., Ruggiero Neto J., de Azevedo W.F. Jr. Crystal structure of human uropepsin at 2.45. Å resolution Acta Crystallogr. D. 57:2001;1560-1570.
28. De Azevedo W.F. Jr., Canduri F., Fadel V., Teodoro L.G.V.L., Hial V., Gomes R.A.S. Molecular model for the binary complex of uropepsin and pepstatin. Biochem. Biophys. Res. Commun. 287(1):2001;277-281.
29. De Azevedo W.F. Jr., Canduri F., da Silveira N.J.F. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem. Biophys. Res. Commun. 293:2002;566-571.
30. De Azevedo W.F. Jr., de Oliveira J.S., Basso L.A., Palma M.S., Pereira J.H., Canduri F., Santos D.S. Molecular model of Shikimate kinase from Mycobacterium tuberculosis. Biochem. Biophys. Res. Commun. 295(1):2002;142-148.
31. De Azevedo W.F. Jr., Gaspar R.T., Canduri F., Camera J.C., da Silveira N.J.F. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine. Biochem. Biophys. Res. Commun. 297:2002;1154-1158.
32. Kim S.-H., Schulze-Gahmen U., Brandsen J., de Azevedo W.F. Jr. Structural basis for chemical inhibitor of CDK2. Prog. Cell Cycle Res. 2:1996;137-145.
33. De Azevedo W.F. Jr., Mueller-Dieckmann H.J., Schulze-Gahmen U., Worland P.J., Sausville E., Kim S.-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA. 93(7):1996;2735-2740.
34. De Azevedo W.F. Jr., Leclerc S., Meijer L., Havlicek L., Strnad M., Kim S.-H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human CDK2 complexed with roscovitine. Eur. J. Biochem. 243:1997;518-526.
35. De Azevedo W.F., Gaspar R.T., Canduri F., Camera J.C., da Silveira N.J.F. Molecular model of cyclin-dependent kinase 5 complexed with Roscovitine. Biochem. Biophys. Res. Commun. 297(5):2002;1154-1158.
36. Montgomery J.A. Purine nucleoside phosphorylase: a target for drug design. Med. Res. Rev. 13(3):1993;209-228.
37. Miles R.W., Tyler P.C., Furneaux R.H., Bagdassarian C.K., Schramm V.L. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry. 37:1998;8615-8621.
38. Kicska G.A., Tyler P.C., Evans G.B., Furneaux R.H., Shi W., Fedorov A., Lewandowicz A., Cahill S.M., Almo S.C., Schramm V.L. Atomic dissection of the hydrogen bond network for transition-state analogue binding to purine nucleoside phosphorylase. Biochemistry. 41(49):2002;14489-14498.
39. Nicholls A., Sharp K., Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins Struct. Funct. Genet. 11:1991;281-296.
40. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of proteins. J. Appl. Crystallogr. 24:1991;946-950.
41. Merritt E.A., Bacon D.J. Raster3D: Photorealistic Molecular Graphics. Methods Enzymol. 277:1997;505-524.